Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Company Achievements - Launched Revuforj® (revumenib), the first and only FDA-approved menin inhibitor, for the treatment of relapsed or refractory (R/R) acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older [2][6] - Revumenib was added to the NCCN Clinical Practice Guidelines for AML and ALL as a category 2A recommendation for R/R acute leukemia with a KMT2A rearrangement [2][6] - Received FDA approval for Niktimvo™ (axatilimab-csfr) for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg [2][10] - Announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo, which is expected to help the company reach profitability [7] Clinical Trial Results - Met the primary endpoint in the Phase 2 cohort of the AUGMENT-101 trial of revumenib in 64 adults with R/R mNPM1 AML [6] - Reported an overall response rate (ORR) of 100$350 million royalty funding agreement, is expected to fund operations through profitability [7]